Memphasys

Memphasys Debt

The Debt of Memphasys (MEM.AX) as of Oct 19, 2026 is 4.24 M AUD. In the previous year, Debt was 5.11 M AUD — a change of -16.87% (lower).

Debt

4.24 MAUD

YoY

-16.87%

Last updated:

In 2026, Memphasys's total debt was 4.24 M AUD, a -16.87% change from the 5.11 M AUD total debt recorded in the previous year.

The Memphasys Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2019
6,748.00 AUD
Jan 1, 2020
1.07 M AUD
Jan 1, 2021
5.36 M AUD
Jan 1, 2022
5.56 M AUD
Jan 1, 2023
6.37 M AUD
Jan 1, 2024
4.81 M AUD
Jan 1, 2025
5.11 M AUD
Jan 1, 2026
4.24 M AUD
The Memphasys Debt history
YEARDebtYoY
4.24 MAUD-16.87%
5.11 MAUD+6.16%
4.81 MAUD-24.53%
6.37 MAUD+14.56%
5.56 MAUD+3.82%
5.36 MAUD+402.01%
1.07 MAUD+15,715.65%
6,748.00AUD-98.60%
482,038.00AUD-92.85%
6.74 MAUD+37.92%
4.89 MAUD-9.03%
5.37 MAUD-20.03%
6.72 MAUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Memphasys Stock analysis

What does Memphasys do? Memphasys Ltd, listed on the Australian Securities Exchange under the ticker MEM.AX, is a life sciences company headquartered in Homebush West, New South Wales. The company went public via an IPO on May 14, 2007. Memphasys operates within the Health Care sector, specifically in the Life Sciences Tools & Services industry. The company focuses on developing medical devices, diagnostics, and media for applications in assisted reproduction technology (ART) for both humans and animals. Its product pipeline includes several developments, such as Felix, ROSA, and AI-Port. Felix is a patented, automated device designed to separate high-quality sperm from semen for human in vitro fertilization (IVF) procedures, aiming to avoid DNA damage. ROSA functions as an in vitro diagnostic tool to evaluate semen and blood samples for oxidative stress. AI-Port is a system for storing and transporting animal semen for artificial insemination (AI) in livestock, capable of maintaining semen viability for up to four days without freezing, which is a common practice in standard AI procedures. The company's products target global markets, particularly in the field of reproductive biotechnology, with specific applications in both human and animal reproductive health. Memphasys operates with a focus on innovation in reproductive technology, leveraging proprietary media and diagnostic tools to address challenges in assisted reproduction. Memphasys is one of the most popular companies on Eulerpool.

Debt Details

Understanding Memphasys's Debt Structure

Memphasys's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Memphasys's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Memphasys’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Memphasys’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Memphasys stock

Debt of Memphasys is 4.24 M AUD in 2026.

Debt of Memphasys changed from 5.11 M AUD to 4.24 M AUD, representing a -16.87% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Memphasys since 2006 – with annual values, charts, and detailed analysis.

Debt's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Memphasys historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Memphasys

All Key Metrics — Memphasys